Rimmyrah (ranibizumab biosimilar) / Biocad, Qilu Pharma - LARVOL DELTA

A comparative study on the efficacy and safety of biosimilar (Rimmyrah) and reference ranibizumab in patients with diabetic macular edema. (PubMed, Front Pharmacol) - "No treatment-related serious ocular or systemic adverse events occurred in either group during the 12-month follow-up. The ranibizumab biosimilar (Rimmyrah) showed similar safety and efficacy profiles to its reference product in the treatment of diabetic macular edema."

Journal • Diabetic Macular Edema • Ophthalmology

Comparison of the Effects of Biosimilar QL1205 and Lucentis® on OCTA and Aqueous Humor Biomarkers in Patients with Macular Edema due to Retinal Vein Occlusion (ChiCTR) - P4 | N=60 | Not yet recruiting | Sponsor: Bengbu Municipal Second People Hospital; Bengbu Municipal Second People Hospital

New P4 trial • Macular Edema • Ophthalmology • Retinal Vein Occlusion

Efficacy and Safety of Ranibizumab Biosimilar QL1205 in Neovascular Age-related Macular Degeneration: A Phase 3 Randomized Trial. (PubMed, Ophthalmol Retina) - "QL1205 was biosimilar to reference ranibizumab regarding clinical efficacy, ocular and systemic safety, as well as immunogenicity and pharmacokinetics profiles in the treatment of patients with nAMD."

Journal • P3 data • Age-related Macular Degeneration • Diabetic Retinopathy • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration